INDV (Indivior Pharmaceuticals) Short-Term Debt: $0 Mil (As of Mar. 2026)


INDV Indivior Pharmaceuticals Inc INDV
75 GF Score
Price $40.50
GF Value $22.93
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Indivior Pharmaceuticals Short-Term Debt?

Indivior Pharmaceuticals INDV -1.94% 75 Short-Term Debt is $0 Mil as of Mar. 2026. GuruFocus rates INDV with a GF Score™ of 75/100 and a GF Value™ of $22.93 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Indivior Pharmaceuticals's Short-Term Debt for the quarter that ended in Mar. 2026 was $0 Mil.

Indivior Pharmaceuticals's quarterly Short-Term Debt increased from Sep. 2025 ($18 Mil) to Dec. 2025 ($29 Mil) but then declined from Dec. 2025 ($29 Mil) to Mar. 2026 ($0 Mil).

Indivior Pharmaceuticals's annual Short-Term Debt increased from Dec. 2023 ($3 Mil) to Dec. 2024 ($18 Mil) and increased from Dec. 2024 ($18 Mil) to Dec. 2025 ($29 Mil).

Indivior Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Indivior Pharmaceuticals Short-Term Debt Related Terms

Indivior Pharmaceuticals Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Indivior Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indivior Pharmaceuticals Short-Term Debt Chart

Indivior Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 3.00 3.00 18.00 29.00

Indivior Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.00 18.00 18.00 29.00 0.00
INDV
75GF Score
Indivior Pharmaceuticals Inc INDV
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0 Mil mean?
Indivior Pharmaceuticals (INDV) has a Short-Term Debt of $0 Mil as of Mar. 2026.
Is Indivior Pharmaceuticals' Short-Term Debt too high?
Indivior Pharmaceuticals' current Short-Term Debt is $0 Mil. Overall, Indivior Pharmaceuticals has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Indivior Pharmaceuticals' Short-Term Debt compare to KNSA and AMRX?
Indivior Pharmaceuticals' Short-Term Debt of $0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Indivior Pharmaceuticals's current Short-Term Debt is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indivior Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Indivior Pharmaceuticals (INDV) is currently considered Significantly Overvalued. The stock's GF Value™ is $22.93, compared to a current price of $40.50 — trading 76.6% above its estimated fair value. The current Short-Term Debt is $0 Mil. Indivior Pharmaceuticals' overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Indivior Pharmaceuticals (INDV), the current Short-Term Debt is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Indivior Pharmaceuticals (INDV) Overvalued in 2026?

Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued. The current stock price of $40.50 is trading 76.6% above its estimated GF Value™ of $22.93. GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for INDV:

  • Short-Term Debt: $0 Mil
  • GF Value™: $22.93 vs. price of $40.50 (76.6% above fair value)
  • GF Score™: 75/100 with 6 warning signs

No single metric tells the full story. See the INDV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Indivior Pharmaceuticals Business Description

Other Exchanges E7P:Germany
Address 10710 Midlothian Turnpike, Suite 125, North Chesterfield, Richmond, VA, USA, 23235
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
75GF Score

Get the complete analysis for INDV

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$40.50
Price
$22.93
GF Value